Pramipexole

Pramipexole
Clinical data
Pronunciation/ˌpræmɪˈpɛksoʊl/
Trade namesMirapex, Mirapexin, Sifrol, others
AHFS/Drugs.comMonograph
MedlinePlusa697029
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability>90%
Protein binding15%
Elimination half-life8–12 hours
ExcretionUrine (90%), feces (2%)
Identifiers
IUPAC name
  • (S)-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.124.761
Chemical and physical data
FormulaC10H17N3S
Molar mass211.33 g·mol−1
3D model (JSmol)
SMILES
  • n1c2c(sc1N)C[C@@H](NCCC)CC2
InChI
  • InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1 Y
  • Key:FASDKYOPVNHBLU-ZETCQYMHSA-N Y
  (verify)

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome.[8] In Parkinson's disease it may be used alone or together with levodopa.[8] It is taken by mouth.[8] Pramipexole is a dopamine agonist of the non-ergoline class.[8]

Pramipexole was approved for medical use in the United States in 1997[8] and was first manufactured by Pharmacia and Upjohn.[9] It is available as a generic medication.[10] In 2022, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.[11][12]

  1. ^ Cite error: The named reference Preg2019 was invoked but never defined (see the help page).
  2. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  3. ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
  4. ^ Cite error: The named reference Mirapex FDA label was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference Mirapex ER FDA label was invoked but never defined (see the help page).
  6. ^ "Sifrol EPAR". European Medicines Agency. 17 November 2009. Archived from the original on 18 October 2020. Retrieved 17 October 2020.
  7. ^ "Mirapexin EPAR". European Medicines Agency. 17 November 2009. Archived from the original on 18 October 2020. Retrieved 17 October 2020.
  8. ^ a b c d e "Pramipexole Dihydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 3 April 2019. Retrieved 22 March 2019.
  9. ^ Wilson SM, Wurst MG, Whatley MF, Daniels RN (2 September 2020). "Classics in Chemical Neuroscience: Pramipexole". ACS Chemical Neuroscience. 11 (17): 2506–2512. doi:10.1021/acschemneuro.0c00332. PMID 32786316.
  10. ^ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 417–418. ISBN 978-0-85711-338-2.
  11. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  12. ^ "Pramipexole Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.